Cargando…

Dealing with Posttraumatic Nightmares

INTRODUCTION: Posttraumatic nightmares are one of the most frequent symptoms in posttraumatic stress disorder. Prevalence can be up to 96%. These nightmares evoke the experienced traumatic event, causing a negative impact. Besides, they are and independent risk for suicide. There are different pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez Garcia, C., Nocete Navarro, L., Sanz Giancola, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567030/
http://dx.doi.org/10.1192/j.eurpsy.2022.1735
_version_ 1784809298923094016
author Alvarez Garcia, C.
Nocete Navarro, L.
Sanz Giancola, A.
author_facet Alvarez Garcia, C.
Nocete Navarro, L.
Sanz Giancola, A.
author_sort Alvarez Garcia, C.
collection PubMed
description INTRODUCTION: Posttraumatic nightmares are one of the most frequent symptoms in posttraumatic stress disorder. Prevalence can be up to 96%. These nightmares evoke the experienced traumatic event, causing a negative impact. Besides, they are and independent risk for suicide. There are different pharmacological and non-pharmacological options for PTN, despite is no optimal treatment. OBJECTIVES: To analyse the different treatment options for PTN. METHODS: This was a narrative literature review. RESULTS: The two main treatments for PTN nowadays are the Imagery Rehearsal Therapy (IRT) and prazosin. IRT is a cognitive-behavioral intervention, that helps the patient to change the content of the nightmare to a “happier ending”. Prazosin is an alpha-adrenergic receptor antagonist that blocks the stress response in the central nervous system receptors. Although it was a promising drug, significant differences compared to placebo have not been found. There is growing data that suggests nabilone, a synthetic cannabinoid, could be helpful in PTN treatment. A clinical trial made in Canada revealed that 72% of patients experienced a complete disappearance or at least an important reduction of PTN. CONCLUSIONS: PTN is a very common and distressing symptom in patients presenting PTSD. Nevertheless, there is no treatment with enough evidence for this pathology. On this account, it is fundamental to do more research in order to find and suitable treatment that can improve the quality of life of these patients. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9567030
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95670302022-10-17 Dealing with Posttraumatic Nightmares Alvarez Garcia, C. Nocete Navarro, L. Sanz Giancola, A. Eur Psychiatry Abstract INTRODUCTION: Posttraumatic nightmares are one of the most frequent symptoms in posttraumatic stress disorder. Prevalence can be up to 96%. These nightmares evoke the experienced traumatic event, causing a negative impact. Besides, they are and independent risk for suicide. There are different pharmacological and non-pharmacological options for PTN, despite is no optimal treatment. OBJECTIVES: To analyse the different treatment options for PTN. METHODS: This was a narrative literature review. RESULTS: The two main treatments for PTN nowadays are the Imagery Rehearsal Therapy (IRT) and prazosin. IRT is a cognitive-behavioral intervention, that helps the patient to change the content of the nightmare to a “happier ending”. Prazosin is an alpha-adrenergic receptor antagonist that blocks the stress response in the central nervous system receptors. Although it was a promising drug, significant differences compared to placebo have not been found. There is growing data that suggests nabilone, a synthetic cannabinoid, could be helpful in PTN treatment. A clinical trial made in Canada revealed that 72% of patients experienced a complete disappearance or at least an important reduction of PTN. CONCLUSIONS: PTN is a very common and distressing symptom in patients presenting PTSD. Nevertheless, there is no treatment with enough evidence for this pathology. On this account, it is fundamental to do more research in order to find and suitable treatment that can improve the quality of life of these patients. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9567030/ http://dx.doi.org/10.1192/j.eurpsy.2022.1735 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Alvarez Garcia, C.
Nocete Navarro, L.
Sanz Giancola, A.
Dealing with Posttraumatic Nightmares
title Dealing with Posttraumatic Nightmares
title_full Dealing with Posttraumatic Nightmares
title_fullStr Dealing with Posttraumatic Nightmares
title_full_unstemmed Dealing with Posttraumatic Nightmares
title_short Dealing with Posttraumatic Nightmares
title_sort dealing with posttraumatic nightmares
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567030/
http://dx.doi.org/10.1192/j.eurpsy.2022.1735
work_keys_str_mv AT alvarezgarciac dealingwithposttraumaticnightmares
AT nocetenavarrol dealingwithposttraumaticnightmares
AT sanzgiancolaa dealingwithposttraumaticnightmares